Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28736317 | 0.94 | CA1 (0.47) | MAPTHPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL300884 | 0.91 | CA12 (0.42) | MAPTHPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL19150003 | 0.89 | HPGD (0.37) | MAPTHPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL14640220 | 0.86 | ALDH1A1 (0.54) | MAPTHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL8433813 | 0.86 | KMT2A (0.50) | MAPTHPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL13455758 | 0.85 | SMN1; SMN2 (0.44) | HPGDRAB9AALDH1A1KMT2ALMNA | |
| SCHEMBL5648489 | 0.84 | CA12 (0.47) | MAPTHPGDRAB9AALDH1A1KMT2A | |
| SCHEMBL4393639 | 0.83 | TSHR (0.45) | ALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7740161 | 0.83 | CA1 (0.55) | MAPTHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL21998937 | 0.83 | MAPT (0.40) | MAPTHPGDRAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497417-B2 | Delivery systems for controlled drug release | LADRX CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | disclosed |
| CN-115089722-A | Delivery system for controlled drug release | 森托瑞恩生物制药公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| CN-107922457-B | Delivery system for controlled drug release | 森托瑞恩生物制药公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3954394-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | Centurion BioPharma Corporation (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3310800-B1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CENTURION BIOPHARMA CORP (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20210325376-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MED SYST INC (US) | 2021-10-21 | — | — | US | disclosed |
| US-11079372-B2 | Polymers and conjugates comprising the same | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-10696699-B2 | Charged linkers and their uses for conjugation | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-6911535-B2 | Covalently linking natural or synthetic biomolecule to a mono-or bi-functional polymer; covalently and/or electrostatically immobilizing biomolecule/polymer conjugate to a unmodified or modified surface | SOLVLINK BIOSCIENCES (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1351991-A4 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2004-10-28 | — | — | US | disclosed |
| US-6686461-B1 | HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION | SOLULINK BIOSCIENCE, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1351991-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | Schwartz, David A. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | AUDAX PRIVATE DEBT LLC, AS AGENT | 2002-10-10 | — | — | US | disclosed |
| WO-2002057422-A2 | TERNARY BIOMOLECULE/POLYMER/SURFACE-BASED IMMOBILIZATION SYSTEMS | SCHWARTZ DAVID A (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002010431-A2 | FUNCTIONAL BIOPOLYMER MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020146504-A1 | Ternary biomolecule/polymer/surface-based immobilization systems | EPCAM, DNPEP, ANPEP | MAPT 4178/4885HPGD 3801/4885RAB9A 4795/4885 |
| US-11384104-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | MAPT 565/4885HPGD 662/4885RAB9A 1629/4885 |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | MAPT 4128/4885HPGD 793/4885RAB9A 4795/4885 |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | MAPT 565/4885HPGD 662/4885RAB9A 1629/4885 |
| US-12497417-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | MAPT 565/4885HPGD 662/4885RAB9A 1629/4885 |
| US-10696699-B2 | Charged linkers and their uses for conjugation | PHOSPHO1, PCTP, CD2BP2 | MAPT 3444/4885HPGD 3704/4885RAB9A 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.